Dashboard
Manage Tickers

CYCCPCyclacel Pharmaceuticals, Inc.

Nasdaq cyclacel.com


$ 8.00 $ -0.72 (-8.49 %)    

Monday, 09-Sep-2024 15:03:51 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 468.28 $ 9.96 (2.17 %)
DIA $ 409.73 $ 1.01 (0.25 %)
SPY $ 554.79 $ 5.63 (1.03 %)
TLT $ 100.61 $ -0.08 (-0.08 %)
GLD $ 232.25 $ -0.37 (-0.16 %)
$ 7.76
$ 6.29 x 100
-- x --
-- - --
$ 5.21 - $ 22.20
200
na
2.15M
$ 0.01
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-14-2024 03-31-2024 10-Q
3 03-21-2024 12-31-2023 10-K
4 11-29-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-08-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-30-2022 12-31-2021 10-K
12 11-12-2021 09-30-2021 10-Q
13 08-12-2021 06-30-2021 10-Q
14 05-14-2021 03-31-2021 10-Q
15 03-01-2021 12-31-2020 10-K
16 11-12-2020 09-30-2020 10-Q
17 08-13-2020 06-30-2020 10-Q
18 05-12-2020 03-31-2020 10-Q
19 03-05-2020 12-31-2019 10-K
20 11-13-2019 09-30-2019 10-Q
21 08-13-2019 06-30-2019 10-Q
22 05-14-2019 03-31-2019 10-Q
23 03-28-2019 12-31-2018 10-K
24 11-13-2018 09-30-2018 10-Q
25 08-09-2018 06-30-2018 10-Q
26 05-14-2018 03-31-2018 10-Q
27 03-30-2018 12-31-2017 10-K
28 11-13-2017 09-30-2017 10-Q
29 08-10-2017 06-30-2017 10-Q
30 05-12-2017 03-31-2017 10-Q
31 03-31-2017 12-31-2016 10-K
32 11-14-2016 09-30-2016 10-Q
33 08-11-2016 06-30-2016 10-Q
34 05-13-2016 03-31-2016 10-Q
35 03-29-2016 12-31-2015 10-K
36 11-12-2015 09-30-2015 10-Q
37 08-12-2015 06-30-2015 10-Q
38 05-12-2015 03-31-2015 10-Q
39 03-31-2015 12-31-2014 10-K
40 11-12-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Cyclacel's Fadraciclib Reports Efficacy In...
06/04/2024 12:27:03

 - Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action -BERKELEY HEIGH...

Core News & Articles
Cyclacel Pharmaceuticals To Present Clinic...
06/03/2024 12:38:57

- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study i...

12-health-care-stocks-moving-in-fridays-intraday-session
12 Health Care Stocks Moving In Friday's I...
04/12/2024 16:31:01

Core News & Articles
Cyclacel Pharmaceuticals To Present New Cl...
04/01/2024 13:16:41

- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program ...

Core News & Articles
Cyclacel Pharmaceuticals Announces Preclin...
03/07/2024 14:24:48

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )))), a biopharmac...

Core News & Articles
Cyclacel Pharmaceuticals Announces Receipt...
03/06/2024 14:25:40

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )))), a biopharmac...

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
01/11/2024 17:31:07

Core News & Articles
Cyclacel Pharmaceuticals Announces $1.3M R...
12/22/2023 14:19:28

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )))), a biopharmac...

Core News & Articles
Cyclacel Pharmaceuticals Reports Fadracicl...
12/18/2023 14:04:07

- Patient Pharmacodynamic Data Show Decrease in CDKN2A, CDKN2B, and PRMT5 Protein Levels -   - A Squamous Non-Small Cell Lung ...

Core News & Articles
Cyclacel Regains Compliance With Nasdaq Li...
11/30/2023 14:19:04

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )))), a biopharmac...

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
11/09/2023 17:31:40

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
11/02/2023 17:31:16

12-health-care-stocks-moving-in-fridays-intraday-session
12 Health Care Stocks Moving In Friday's I...
06/02/2023 17:31:42

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
05/17/2023 17:31:40

Core News & Articles
Cyclacel Pharmaceuticals Announces Receipt...
05/03/2023 13:16:11

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical...

Core News & Articles
Cyclacel Pharmaceuticals Reviews 2022 Achi...
01/05/2023 14:16:38

– Determination of Recommended Phase 2 Dose and Start of Phase 2 in 1Q 2023 for Oral Fadraciclib – – 2/3 Partial Responses in ...

Core News & Articles
Cyclacel Reports Preliminary Data From Pha...
10/26/2022 13:16:39

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, Cyclacel or the Company)))), a biopharmaceutical company developing ...

Core News & Articles
Cyclacel Pharmaceuticals To Present Prelim...
10/13/2022 13:17:20

 Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", , Cyclacel", , or the ", , Company", , )))), a b...

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
06/08/2022 17:53:43

 

Core News & Articles
Cyclacel Announces Dosing Of First Patient...
04/19/2022 13:17:38

- CYC140, a Potent and Selective PLK1 Inhibitor to Be Evaluated as a Single Agent Across Multiple Solid Tumor and Lymphoma Typ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION